Payment overview · 2025
General Payments
$3,266.46
106 reported records · 20 companies
Healthcare provider profile · identity verified
Brandi Greeson, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DECATUR, AL · NPI 1982169470
Verified facts
What the public records show
CMS Open Payments records show Brandi Greeson, CRNP received $3,266.46 in general payments during 2025 across 106 reported records.
Inspire Medical Systems, Inc. accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $1,337.78 | 41.0% | 19 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $282.28 | 8.6% | 12 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $256.45 | 7.8% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $202.35 | 6.2% | 9 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $168.49 | 5.2% | 8 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $163.23 | 5.0% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $115.93 | 3.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.88 | 3.2% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $89.99 | 2.8% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $87.52 | 2.7% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $68.49 | 2.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.38 | 1.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.77 | 1.7% | 3 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $50.27 | 1.5% | 2 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $49.50 | 1.5% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $44.62 | 1.4% | 8 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $37.60 | 1.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.10 | 1.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.34 | 0.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $22.49 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,227.55 | 101 |
| Travel and Lodging | $948.92 | 4 |
| Education | $89.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $1,337.78 | 19 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $282.28 | 12 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $274.41 | 8 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $256.45 | 9 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $202.35 | 9 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $168.49 | 8 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $163.23 | 6 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $99.66 | 6 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $87.52 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.77 | 3 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $50.27 | 2 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $49.50 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $44.62 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.32 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $37.60 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 87 |
| Losartan Potassium | Losartan Potassium | 109 | 50 |
| Metformin Hcl | Metformin Hcl | 107 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 45 |
| Lisinopril | Lisinopril | 74 | 41 |
| Omeprazole | Omeprazole | 71 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 32 |
| Potassium Chloride | Potassium Chloride | 58 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 11 |
| Carvedilol | Carvedilol | 46 | 25 |
| Meloxicam | Meloxicam | 46 | 22 |
| Jardiance | Empagliflozin | 45 | 11 |
| Montelukast Sodium | Montelukast Sodium | 44 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 11 |
| Sertraline Hcl | Sertraline Hcl | 30 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | 11 |
| Trazodone Hcl | Trazodone Hcl | 24 | 13 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Furosemide | Furosemide | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,266.46 · 106 records | Inspire Medical Systems, Inc. | AIRSUPRA, AREXVY, Azstarys, DUPIXENT, GLASSIA, INSPIRE, JASCAYD, LUMRYZ, LUNA, OFEV, Prolastin-C Liquid, Quviviq, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und, WAKIX, XYWAV, YUPELRI, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error